Blockbuster Biologics 2017: Sales of Recombinant Therapeutic Antibodies & Proteins - ResearchAndMarkets.com

DUBLIN--()--The "Blockbuster Biologics 2017: Sales of Recombinant Therapeutic Antibodies & Proteins" report has been added to ResearchAndMarkets.com's offering.

This report provides a compilation of the sales data of originator recombinant therapeutic proteins and antibodies in the calendar year 2017.

Sales data were obtained from company publications and refer to branded products originating from companies based in regulated markets. All sales data were converted from their original, reported currency into US$ using official currency exchange rates as of March 18 2017. Sales figures represent the sum of revenues in all territories where the products are marketed. Growth rates mostly are presented as reported (in some cases on constant exchange rates).

A total of 45 biologic therapeutics reached blockbuster status with 2017 sales exceeding US$ 1 bln: 27 antibodies and 18 proteins. Fourteen new biologics with sales data were included fort he first time in this compilation. Ten biologics reached global sales in 2017 of more than US$ 5 bln. Three biologics were new in the blockbuster biologics list. In addition, commercial information about sales of selected biosimilars of recombinant antibodies and proteins is provided.

Sales data are presented for each product within the respective class of biologics. The data were analyzed to establish a ranking list of blockbuster biologics with 2017 sales higher than US$ 1 bln. Another ranking list was prepared for TOP 30 companies according to biologics sales in 2017 and the percentage of antibody sales of total biologics sales.

Key Topics Covered:

1 2017 Biologics Sales per Class of Branded Originator Products

2 Blockbuster Biologics in 2017 (by generic name)

3 TOP 30 Company Ranking List for Biologics Sales 2017

4 Currency Exchange Rates

5 Biologic Product Sales 2017

  • Cancer Antibodies
  • Anti-TNF Antibodies
  • Other Anti-Inflammatory and Anti-Autoimmune Antibodies
  • Insulin and Insulin Analogs
  • Ophthalmic Antibodies
  • Recombinant Coagulation Factors
  • Cardiometabolic & Anti-Infective Antibodies
  • Enzyme Replacement Proteins (ERT)
  • Erythropoietins
  • G-CSF
  • Interferon beta
  • Human Growth Hormone (hGH)
  • Follicle Stimulating Hormone (FSH)
  • Other Proteins: Cardiometabolic, Cancer & Others
  • Selected Biosimilar Antibodies & Proteins

For more information about this report visit https://www.researchandmarkets.com/research/35wll4/blockbuster?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Immune Disorders Drugs, Biopharmaceuticals

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Immune Disorders Drugs, Biopharmaceuticals